The orexigenic peptide hormone ghrelin exerts potent inhibitory effects on pro-inflammatory cytokine release via the growth hormone secretagogue receptor-1a (GHS-R1a) on T cells and monocytes. As such, ghrelin is a promising therapeutic agent for the treatment of inflammatory conditions, but these effects depend on the availability of GHS-R1a. The aim of this study was to determine the effect of acute exercise on GHS-R1a expression on circulating CD14+ monocytes, total lymphocytes and CD3+ T cells. Nine male club-standard cyclists cycled for 1 h at 75% _ VO 2peak (EX) or rested (REST) in a randomised cross-over design. Compared with the equivalent times in REST, the concentration of circulating GHS-R1a+ lymphocytes and monocytes was higher in EX at immediately and 1 and 2 h post-exercise (all p < .05). The concentration of CD3+GHS-R1a+ cells was higher in EX than in REST immediately post-exercise only (258 (203) cells ll À1 vs. 62 (42) cells ll À1 , p < .05). Density of GHS-R1a receptor expression was unaffected by trial or time. Comparison of active participants at rest with 7 age-, sex-and BMI-matched sedentary controls revealed a higher concentration of GHS-R1a+ lymphocytes in active males (p < .05). These findings suggest a preferential recruitment of specific cell subpopulations expressing GHS-R1a into the peripheral circulation with acute and regular exercise. Given that the anti-inflammatory effects of ghrelin depend on the availability of GHS-R1a, the preferential recruitment of subpopulations with high antiinflammatory potential found here add a novel aspect to the potential mechanisms by which exercise acts to reduce pro-inflammatory cytokine levels. Crown
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Introduction
There is increasing evidence of the coupling of immune status to the metabolic system (Dixit and Taub, 2005; Karalis et al., 2009; Odegaard and Chawla, 2013) . This communication is mediated via a complex array of cytokines, hormones and neuropeptides. Ghrelin, an orexigenic peptide hormone, is predominantly produced by the X/A-like cells within the oxyntic mucosa of the stomach and has been primarily studied in relation to the regulation of food intake and its action in stimulating growth hormone release from the anterior pituitary gland. Aside from these well-studied effects, ghrelin is now known to play a key role in the regulation of inflammation, with reports of inhibitory effects of the acylated (but not des-acylated) isoform of ghrelin on IL-1b, IL-6 and TNF-a mRNA and protein expression in both human and rodent T cells and monocytes in vivo and in vitro (Dixit et al., 2004; DeBoer et al., 2008; Waseem et al., 2008) . Acylated ghrelin also attenuates leptin-induced pro-inflammatory cytokine responses in human monocytes and T cells (Dixit et al., 2004) . These cytokines are believed to mediate loss of appetite or anorexia commonly associated with inflammation, injury or illness (Kelley et al., 2003) and their overexpression can lead to a catabolic state and cachexia (Dixit and Taub, 2005) . With this in mind, acylated ghrelin has been proposed as a promising therapeutic agent for the treatment of a host of cachectic and other chronic inflammatory conditions including cancer cachexia, cardiovascular, respiratory and kidney diseases, inflammatory bowel diseases and age-associated inflammation (Baatar et al., 2011; DeBoer, 2011; Steinman and DeBoer, 2013) . However, while initial findings have been promising, the safety of long-term ghrelin treatment is still unknown (Strasser et al., 2008; DeBoer, 2011) .
The effects of acylated ghrelin on immune cell cytokine release are dependent on the availability of its target receptor, the growth hormone secretagogue receptor-1a (GHS-R1a) (Dixit et al., 2004) . GHS-R1a has been demonstrated on various immune cell subsets, including T cells, B cells, monocytes and neutrophils (Hatttori et al., 2001; Dixit et al., 2004) . Expression of GHS-R1a mRNA and protein by human T cells is increased by 3-4-fold upon activation with the mitogens phytohemagglutinin and concanavalin A, with
